ABSTRACT
Objective:
Severe
pancreatitis presents a formidable clinical challenge, often associated with high
mortality rates and compromised
quality of life. This study aimed to assess the
efficacy of combining ulinastatin with
somatostatin in treating severe
pancreatitis, with a focus on improving
patient outcomes.
Methods:
We conducted a study on 98 severe
pancreatitis patients at our
hospital from January 2022 to March 2023. These
patients were randomly divided into two groups a
control group (n=49) treated with
somatostatin and an experimental group (n=49) treated with ulinastatin plus
somatostatin. The
control group received 250 micrograms per hour of
somatostatin intravenously for 72 hours. The experimental group received 200 000 units of ulinastatin every 8 hours intravenously, along with the same
somatostatin regimen. We compared
clinical efficacy, inflammatory markers (TNF-α, CRP,
IL-6),
hemodynamic parameters (MAP, CVP, HR, SVR), and immune
cell function between the groups.
Results:
Post-
treatment, the experimental group showed significant improvements compared to the
control group (P < .05) in various
parameters. Decreases in AMS, TNF-α, CRP,
IL-6, MAP, CVP, and CD8+
T-cells were more pronounced in the experimental group. Notably, AMS levels dropped from 450 U/L to 150 U/L, and TNF-α levels from 55 pg/mL to 20 pg/mL in the experimental group. Conversely, increases in HR, SVR, CD4+
T-cells, CD4+/CD8+ ratio, and
NK cell counts were observed. For instance, CD4+
T-cells rose from 300
cells/µL to 500
cells/µL. The experimental group exhibited a higher
clinical efficacy rate of 97.96%, compared to 85.71% in the
control group. The combined
treatment of ulinastatin with
somatostatin demonstrated significant
effectiveness in improving clinical outcomes compared to the
control group.
Statistical analysis robustly supported these findings, providing confidence in their reliability. Importantly, the combined
therapy showed promise in reducing
mortality rates and enhancing the
quality of life for
patients with severe
pancreatitis.
Conclusion:
The findings of this study hold substantial clinical implications, potentially influencing
treatment protocols and
patient management
strategies for severe
pancreatitis. The integration of ulinastatin combined with
somatostatin into standard care
protocols could significantly improve
treatment outcomes and
patient prognosis.